UK Markets closed

Global Next Generation Sequencing (NGS) Data Analysis Market to Reach $1.4 Billion by 2027

·25-min read

Abstract: - Global Next Generation Sequencing (NGS) Data Analysis Market to Reach $1. 4 Billion by 2027. - Amid the COVID-19 crisis, the global market for Next Generation Sequencing (NGS) Data Analysis estimated at US$638.

New York, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Next Generation Sequencing (NGS) Data Analysis Industry" - https://www.reportlinker.com/p06032337/?utm_source=GNW
8 Million in the year 2020, is projected to reach a revised size of US$1.4 Billion by 2027, growing at aCAGR of 12.2% over the period 2020-2027. Services, one of the segments analyzed in the report, is projected to record 12.5% CAGR and reach US$836.2 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Software segment is readjusted to a revised 11.7% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $188.6 Million, While China is Forecast to Grow at 11.7% CAGR
- The Next Generation Sequencing (NGS) Data Analysis market in the U.S. is estimated at US$188.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$249.7 Million by the year 2027 trailing a CAGR of 11.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.7% and 10.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.

- Select Competitors (Total 33 Featured) -

  • Agilent Technologies, Inc.

  • Bio-Rad Laboratories, Inc.

  • Congenica Ltd.

  • DNAnexus Inc.

  • Dnastar, Inc.

  • Eurofins Scientific

  • F. Hoffmann-La Roche Ltd.

  • Fabric Genomics, Inc.

  • Genuity Science

  • Golden Helix, Inc.

  • Illumina, Inc.

  • Intrexon Bioinformatics Germany GmbH

  • Pacific Biosciences of California, Inc.

  • Partek Incorporated

  • PierianDx

  • Qiagen

  • SciGenom Labs Pvt. Ltd.

  • Thermo Fisher Scientific, Inc.




Read the full report: https://www.reportlinker.com/p06032337/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 2: World 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Geographic Region -
Percentage Breakdown of Value Sales for USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets for Years
2020 & 2027

Table 3: World Current & Future Analysis for Services by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 4: World 7-Year Perspective for Services by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027

Table 5: World Current & Future Analysis for Software by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 6: World 7-Year Perspective for Software by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027

Table 7: World Current & Future Analysis for Pharma & Biotech
Entities by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 8: World 7-Year Perspective for Pharma & Biotech Entities
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 9: World Current & Future Analysis for Hospitals &
Clinics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 10: World 7-Year Perspective for Hospitals & Clinics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 11: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 12: World 7-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 13: World Current & Future Analysis for Academic Research
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 14: World 7-Year Perspective for Academic Research by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 15: World Current & Future Analysis for Clinical Research
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 16: World 7-Year Perspective for Clinical Research by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 17: World Current & Future Analysis for Tertiary Data
Analysis by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 18: World 7-Year Perspective for Tertiary Data Analysis
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 19: World Current & Future Analysis for Primary Data
Analysis by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 20: World 7-Year Perspective for Primary Data Analysis by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 21: World Current & Future Analysis for Secondary Data
Analysis by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 22: World 7-Year Perspective for Secondary Data Analysis
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 23: World Current & Future Analysis for In-House by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 24: World 7-Year Perspective for In-House by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027

Table 25: World Current & Future Analysis for Outsourced by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 26: World 7-Year Perspective for Outsourced by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 27: USA Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and
Software - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 28: USA 7-Year Perspective for Next Generation Sequencing
(NGS) Data Analysis by Component - Percentage Breakdown of
Value Sales for Services and Software for the Years 2020 & 2027

Table 29: USA Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech
Entities, Hospitals & Clinics, Other End-Uses, Academic
Research and Clinical Research - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 30: USA 7-Year Perspective for Next Generation Sequencing
(NGS) Data Analysis by End-Use - Percentage Breakdown of Value
Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other
End-Uses, Academic Research and Clinical Research for the Years
2020 & 2027

Table 31: USA Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 32: USA 7-Year Perspective for Next Generation Sequencing
(NGS) Data Analysis by Workflow - Percentage Breakdown of Value
Sales for Tertiary Data Analysis, Primary Data Analysis and
Secondary Data Analysis for the Years 2020 & 2027

Table 33: USA Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 34: USA 7-Year Perspective for Next Generation Sequencing
(NGS) Data Analysis by Mode - Percentage Breakdown of Value
Sales for In-House and Outsourced for the Years 2020 & 2027

CANADA
Table 35: Canada Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and
Software - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 36: Canada 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Sales for Services and Software for the
Years 2020 & 2027

Table 37: Canada Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech
Entities, Hospitals & Clinics, Other End-Uses, Academic
Research and Clinical Research - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 38: Canada 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Sales for Pharma & Biotech Entities,
Hospitals & Clinics, Other End-Uses, Academic Research and
Clinical Research for the Years 2020 & 2027

Table 39: Canada Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 40: Canada 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Sales for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2020 &
2027

Table 41: Canada Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 42: Canada 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Sales for In-House and Outsourced for the Years 2020 &
2027

JAPAN
Table 43: Japan Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and
Software - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 44: Japan 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Sales for Services and Software for the
Years 2020 & 2027

Table 45: Japan Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech
Entities, Hospitals & Clinics, Other End-Uses, Academic
Research and Clinical Research - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 46: Japan 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Sales for Pharma & Biotech Entities,
Hospitals & Clinics, Other End-Uses, Academic Research and
Clinical Research for the Years 2020 & 2027

Table 47: Japan Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 48: Japan 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Sales for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2020 &
2027

Table 49: Japan Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 50: Japan 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Sales for In-House and Outsourced for the Years 2020 &
2027

CHINA
Table 51: China Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and
Software - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 52: China 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Sales for Services and Software for the
Years 2020 & 2027

Table 53: China Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech
Entities, Hospitals & Clinics, Other End-Uses, Academic
Research and Clinical Research - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 54: China 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Sales for Pharma & Biotech Entities,
Hospitals & Clinics, Other End-Uses, Academic Research and
Clinical Research for the Years 2020 & 2027

Table 55: China Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 56: China 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Sales for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2020 &
2027

Table 57: China Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 58: China 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Sales for In-House and Outsourced for the Years 2020 &
2027

EUROPE
Table 59: Europe Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Geographic Region - France,
Germany, Italy, UK and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 60: Europe 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Geographic Region -
Percentage Breakdown of Value Sales for France, Germany, Italy,
UK and Rest of Europe Markets for Years 2020 & 2027

Table 61: Europe Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and
Software - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 62: Europe 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Sales for Services and Software for the
Years 2020 & 2027

Table 63: Europe Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech
Entities, Hospitals & Clinics, Other End-Uses, Academic
Research and Clinical Research - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 64: Europe 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Sales for Pharma & Biotech Entities,
Hospitals & Clinics, Other End-Uses, Academic Research and
Clinical Research for the Years 2020 & 2027

Table 65: Europe Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 66: Europe 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Sales for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2020 &
2027

Table 67: Europe Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 68: Europe 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Sales for In-House and Outsourced for the Years 2020 &
2027

FRANCE
Table 69: France Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and
Software - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 70: France 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Sales for Services and Software for the
Years 2020 & 2027

Table 71: France Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech
Entities, Hospitals & Clinics, Other End-Uses, Academic
Research and Clinical Research - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 72: France 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Sales for Pharma & Biotech Entities,
Hospitals & Clinics, Other End-Uses, Academic Research and
Clinical Research for the Years 2020 & 2027

Table 73: France Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 74: France 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Sales for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2020 &
2027

Table 75: France Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 76: France 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Sales for In-House and Outsourced for the Years 2020 &
2027

GERMANY
Table 77: Germany Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and
Software - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 78: Germany 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Sales for Services and Software for the
Years 2020 & 2027

Table 79: Germany Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech
Entities, Hospitals & Clinics, Other End-Uses, Academic
Research and Clinical Research - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 80: Germany 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Sales for Pharma & Biotech Entities,
Hospitals & Clinics, Other End-Uses, Academic Research and
Clinical Research for the Years 2020 & 2027

Table 81: Germany Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 82: Germany 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Sales for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2020 &
2027

Table 83: Germany Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 84: Germany 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Sales for In-House and Outsourced for the Years 2020 &
2027

ITALY
Table 85: Italy Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and
Software - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 86: Italy 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Sales for Services and Software for the
Years 2020 & 2027

Table 87: Italy Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech
Entities, Hospitals & Clinics, Other End-Uses, Academic
Research and Clinical Research - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 88: Italy 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Sales for Pharma & Biotech Entities,
Hospitals & Clinics, Other End-Uses, Academic Research and
Clinical Research for the Years 2020 & 2027

Table 89: Italy Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 90: Italy 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Sales for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2020 &
2027

Table 91: Italy Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 92: Italy 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Sales for In-House and Outsourced for the Years 2020 &
2027

UNITED KINGDOM
Table 93: UK Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and
Software - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 94: UK 7-Year Perspective for Next Generation Sequencing
(NGS) Data Analysis by Component - Percentage Breakdown of
Value Sales for Services and Software for the Years 2020 & 2027

Table 95: UK Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Pharma & Biotech
Entities, Hospitals & Clinics, Other End-Uses, Academic
Research and Clinical Research - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 96: UK 7-Year Perspective for Next Generation Sequencing
(NGS) Data Analysis by End-Use - Percentage Breakdown of Value
Sales for Pharma & Biotech Entities, Hospitals & Clinics, Other
End-Uses, Academic Research and Clinical Research for the Years
2020 & 2027

Table 97: UK Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 98: UK 7-Year Perspective for Next Generation Sequencing
(NGS) Data Analysis by Workflow - Percentage Breakdown of Value
Sales for Tertiary Data Analysis, Primary Data Analysis and
Secondary Data Analysis for the Years 2020 & 2027

Table 99: UK Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 100: UK 7-Year Perspective for Next Generation Sequencing
(NGS) Data Analysis by Mode - Percentage Breakdown of Value
Sales for In-House and Outsourced for the Years 2020 & 2027

REST OF EUROPE
Table 101: Rest of Europe Current & Future Analysis for Next
Generation Sequencing (NGS) Data Analysis by Component -
Services and Software - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 102: Rest of Europe 7-Year Perspective for Next
Generation Sequencing (NGS) Data Analysis by Component -
Percentage Breakdown of Value Sales for Services and Software
for the Years 2020 & 2027

Table 103: Rest of Europe Current & Future Analysis for Next
Generation Sequencing (NGS) Data Analysis by End-Use - Pharma &
Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic
Research and Clinical Research - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 104: Rest of Europe 7-Year Perspective for Next
Generation Sequencing (NGS) Data Analysis by End-Use -
Percentage Breakdown of Value Sales for Pharma & Biotech
Entities, Hospitals & Clinics, Other End-Uses, Academic
Research and Clinical Research for the Years 2020 & 2027

Table 105: Rest of Europe Current & Future Analysis for Next
Generation Sequencing (NGS) Data Analysis by Workflow -
Tertiary Data Analysis, Primary Data Analysis and Secondary
Data Analysis - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 106: Rest of Europe 7-Year Perspective for Next
Generation Sequencing (NGS) Data Analysis by Workflow -
Percentage Breakdown of Value Sales for Tertiary Data Analysis,
Primary Data Analysis and Secondary Data Analysis for the Years
2020 & 2027

Table 107: Rest of Europe Current & Future Analysis for Next
Generation Sequencing (NGS) Data Analysis by Mode - In-House
and Outsourced - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 108: Rest of Europe 7-Year Perspective for Next
Generation Sequencing (NGS) Data Analysis by Mode - Percentage
Breakdown of Value Sales for In-House and Outsourced for the
Years 2020 & 2027

ASIA-PACIFIC
Table 109: Asia-Pacific Current & Future Analysis for Next
Generation Sequencing (NGS) Data Analysis by Component -
Services and Software - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 110: Asia-Pacific 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Sales for Services and Software for the
Years 2020 & 2027

Table 111: Asia-Pacific Current & Future Analysis for Next
Generation Sequencing (NGS) Data Analysis by End-Use - Pharma &
Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic
Research and Clinical Research - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 112: Asia-Pacific 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Sales for Pharma & Biotech Entities,
Hospitals & Clinics, Other End-Uses, Academic Research and
Clinical Research for the Years 2020 & 2027

Table 113: Asia-Pacific Current & Future Analysis for Next
Generation Sequencing (NGS) Data Analysis by Workflow -
Tertiary Data Analysis, Primary Data Analysis and Secondary
Data Analysis - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 114: Asia-Pacific 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Sales for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2020 &
2027

Table 115: Asia-Pacific Current & Future Analysis for Next
Generation Sequencing (NGS) Data Analysis by Mode - In-House
and Outsourced - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 116: Asia-Pacific 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Sales for In-House and Outsourced for the Years 2020 &
2027

REST OF WORLD
Table 117: Rest of World Current & Future Analysis for Next
Generation Sequencing (NGS) Data Analysis by Component -
Services and Software - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 118: Rest of World 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Sales for Services and Software for the
Years 2020 & 2027

Table 119: Rest of World Current & Future Analysis for Next
Generation Sequencing (NGS) Data Analysis by End-Use - Pharma &
Biotech Entities, Hospitals & Clinics, Other End-Uses, Academic
Research and Clinical Research - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 120: Rest of World 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Sales for Pharma & Biotech Entities,
Hospitals & Clinics, Other End-Uses, Academic Research and
Clinical Research for the Years 2020 & 2027

Table 121: Rest of World Current & Future Analysis for Next
Generation Sequencing (NGS) Data Analysis by Workflow -
Tertiary Data Analysis, Primary Data Analysis and Secondary
Data Analysis - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 122: Rest of World 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Sales for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2020 &
2027

Table 123: Rest of World Current & Future Analysis for Next
Generation Sequencing (NGS) Data Analysis by Mode - In-House
and Outsourced - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 124: Rest of World 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Sales for In-House and Outsourced for the Years 2020 &
2027

IV. COMPETITION
Total Companies Profiled: 33
Read the full report: https://www.reportlinker.com/p06032337/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting